Finance

Beta
Lists
HLN:NYSE
Haleon PLC - ADR
$9.12
+1.79%
(+0.16) 1D
$9.12
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HLN...
Open
$9.04
High
$9.15
Low
$9.04
Mkt. cap
39.84B
Avg. vol.
8.84M
Volume
10.67M
Dividend
2.12%
Quarterly dividend
$0.05
Ex-dividend date
Apr 9, 2026
P/E ratio
18.40
52-wk high
$11.28
52-wk low
$8.65
EPS
$0.50
Beta
0.15
Shares outstanding
4.42B
No. of employees
25K
Open
$9.04
High
$9.15
Low
$9.04
Mkt. cap
39.84B
Avg. vol.
8.84M
Volume
10.67M
Dividend
2.12%
Quarterly dividend
$0.05
Ex-dividend date
Apr 9, 2026
P/E ratio
18.40
52-wk high
$11.28
52-wk low
$8.65
EPS
$0.50
Beta
0.15
Shares outstanding
4.42B
No. of employees
25K
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to HLN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for HLN in the last 3 months.
Highest
Current $9.12
$13.92 (+52.63%)
Average
$12.46 (+36.62%)
Lowest
$11.00 (+20.61%)
News stories
From sources across the web
Profile
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022. Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Wikipedia
About Haleon PLC - ADR
CEO-
Employees24.5K
FoundedJul 18, 2022
Headquarters-
SectorPharmaceutical industry
Websitehaleon.com
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (GBP)
- / -
Revenue / Est. (GBP)
2.86B / 2.87B
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.74B
2.74B
2.78B
2.78B
Cost of goods sold
972.50M
972.50M
970.50M
970.50M
Cost of revenue
972.50M
972.50M
970.50M
970.50M
Research and development expenses
76.00M
76.00M
81.50M
81.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.08B
1.08B
1.08B
1.08B
Operating expense
1.16B
1.16B
1.16B
1.16B
Total operating expenses
2.13B
2.13B
2.13B
2.13B
Operating income
608.50M
608.50M
643.00M
643.00M
Other non operating income
500.00K
500.00K
-10.50M
-10.50M
EBT including unusual items
537.50M
537.50M
538.50M
538.50M
EBT excluding unusual items
544.50M
544.50M
552.00M
552.00M
Income tax expense
131.00M
131.00M
105.00M
105.00M
Effective tax rate
24.37%
24.37%
19.50%
19.50%
Other operating expenses
-
-
-
-
Net income
403.00M
403.00M
430.50M
430.50M
Net profit margin
14.71%
14.71%
15.51%
15.51%
Earnings per share
-
-
-
-
Interest and investment income
23.50M
23.50M
5.00M
5.00M
Interest expense
-88.00M
-88.00M
-85.50M
-85.50M
Net interest expenses
-64.50M
-64.50M
-80.50M
-80.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
667.00M
667.00M
704.50M
704.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more